	NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
	Guideline
	Asthma: diagnosis, monitoring and chronic asthma management
	Draft for consultation, October 2019
yo pe	<b>his guideline covers</b> diagnosing, monitoring and managing asthma in adults, bung people and children. It aims to improve the accuracy of diagnosis, help eople to control their asthma and reduce the risk of asthma attacks. It does not over managing severe asthma or acute asthma attacks.
W	/ho is it for?
• • •	GPs and practice nurses Healthcare professionals in secondary care and tertiary asthma services Commissioners and providers People with suspected or diagnosed asthma, their families and carers
ΤI	his guideline will update NICE guideline NG80 (published November 2017).
w Y	We have reviewed the evidence on increasing the dose of inhaled corticosteroids ithin a self-management programme in children and young people with asthma. ou are invited to comment on the new and updated recommendations. These are arked as <b>[2020]</b> .
	ou are also invited to comment on recommendations that NICE proposes to elete from the 2017 guideline.
Ca	e have not reviewed the evidence for the recommendations shaded in grey, and annot accept comments on them. In some cases, we have made minor wording nanges for clarification.

See <u>update information</u> for a full explanation of what is being updated.

This draft guideline contains:

- the draft recommendations
- recommendations for research
- rationale and impact sections that explain why the committee made the 2020 recommendations and how they might affect practice
- the guideline context.

Full details of the evidence and the committee's discussion on the 2020 recommendations are in the <u>evidence review</u>. Evidence for the 2017 recommendations is in the <u>full version</u> of the 2017 guideline.

1

# 1 Contents

2	Recom	mendations	4
3	1.1	Initial clinical assessment	4
4	1.2	Diagnosing asthma in young children	6
5	1.3	Objective tests for diagnosing asthma in adults, young people and childre	'n
6	aged	5 and over	6
7	1.4	Diagnostic summary	. 12
8	1.5	Principles of pharmacological treatment	. 16
9	1.6	Pharmacological treatment pathway for adults (aged 17 and over)	. 17
10	1.7	Pharmacological treatment pathway for children and young people aged	
11	5 to 1	16	. 19
12	1.8	Pharmacological treatment pathway for children under 5	. 21
13	1.9	Adherence	. 22
14	1.10	Self-management	. 22
15	1.11	Decreasing maintenance therapy	. 23
16	1.12	Risk stratification	. 24
17	1.13	Monitoring asthma control	. 24
18	Term	is used in this guideline	. 25
19	Putting	this guideline into practice	. 27
20	Recom	mendations for research	. 28
21	Rationa	ale and impact	. 34
22	Contex	t	. 36
23	Finding	more information and resources	. 39
24	Update	information	. 39
25			

## 1 **Recommendations**

People have the right to be involved in discussions and make informed decisions about their care, as described in <u>your care</u>.

<u>Making decisions using NICE guidelines</u> explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

#### 2 1.1 Initial clinical assessment

3 See also <u>algorithm A</u> for initial clinical assessment in adults, young people and

4 children with suspected asthma.

#### 5 Clinical history

- 6 1.1.1 Take a structured clinical history in people with suspected asthma.
- 7 Specifically, check for:
- wheeze, cough or breathlessness, and any daily or seasonal variation
  in these symptoms
- any triggers that make symptoms worse
- a personal or family history of atopic disorders. [2017]
- 12 1.1.2 Do not use symptoms alone without an <u>objective test to diagnose asthma</u>.
  13 [2017]
- 14 1.1.3 Do not use a history of atopic disorders alone to diagnose asthma. [2017]

#### 15 Physical examination

1.1.4 Examine people with suspected asthma to identify <u>expiratory polyphonic</u>
wheeze and signs of other causes of respiratory symptoms, but be aware
that even if examination results are normal the person may still have
asthma. [2017]

1	Initial trea	atment and objective tests for acute symptoms at presentation	
2	1.1.5	Treat people immediately if they are acutely unwell at presentation, and	
3		perform objective tests for asthma (for example, fractional exhaled nitric	
4		oxide [FeNO], spirometry and peak flow variability) if the equipment is	
5		available and testing will not compromise treatment of the acute episode.	
6		[2017]	
7	1.1.6	If objective tests for asthma cannot be done immediately for people who	
8		are acutely unwell at presentation, carry them out when acute symptoms	
9		have been controlled, and advise people to contact their healthcare	
10		professional immediately if they become unwell while waiting to have	
11		objective tests. [2017]	
12	1.1.7	Be aware that the results of spirometry and FeNO tests may be affected in	
13		people who have been treated empirically with inhaled corticosteroids.	
14		[2017]	
4 5	Testing for asthma		
15	resting to	or astrima	
15 16	1.1.8	Do not offer the following as diagnostic tests for asthma:	
	-		
16	-	Do not offer the following as diagnostic tests for asthma:	
16 17	-	<ul><li>Do not offer the following as diagnostic tests for asthma:</li><li>skin prick tests to aeroallergens</li></ul>	
16 17 18	-	<ul> <li>Do not offer the following as diagnostic tests for asthma:</li> <li>skin prick tests to aeroallergens</li> <li>serum total and specific IgE</li> </ul>	
16 17 18 19	-	<ul> <li>Do not offer the following as diagnostic tests for asthma:</li> <li>skin prick tests to aeroallergens</li> <li>serum total and specific IgE</li> <li>peripheral blood eosinophil count</li> </ul>	
16 17 18 19 20	1.1.8	<ul> <li>Do not offer the following as diagnostic tests for asthma:</li> <li>skin prick tests to aeroallergens</li> <li>serum total and specific IgE</li> <li>peripheral blood eosinophil count</li> <li>exercise challenge (to adults aged 17 and over). [2017]</li> </ul>	
16 17 18 19 20 21	1.1.8	<ul> <li>Do not offer the following as diagnostic tests for asthma:</li> <li>skin prick tests to aeroallergens</li> <li>serum total and specific IgE</li> <li>peripheral blood eosinophil count</li> <li>exercise challenge (to adults aged 17 and over). [2017]</li> <li>Use skin prick tests to aeroallergens or specific IgE tests to identify</li> </ul>	
16 17 18 19 20 21 22 23	1.1.8	<ul> <li>Do not offer the following as diagnostic tests for asthma:</li> <li>skin prick tests to aeroallergens</li> <li>serum total and specific lgE</li> <li>peripheral blood eosinophil count</li> <li>exercise challenge (to adults aged 17 and over). [2017]</li> <li>Use skin prick tests to aeroallergens or specific lgE tests to identify triggers after a formal diagnosis of asthma has been made. [2017]</li> </ul>	
16 17 18 19 20 21 22	1.1.8 1.1.9 <b>Occupati</b>	<ul> <li>Do not offer the following as diagnostic tests for asthma:</li> <li>skin prick tests to aeroallergens</li> <li>serum total and specific IgE</li> <li>peripheral blood eosinophil count</li> <li>exercise challenge (to adults aged 17 and over). [2017]</li> <li>Use skin prick tests to aeroallergens or specific IgE tests to identify triggers after a formal diagnosis of asthma has been made. [2017]</li> </ul>	
16 17 18 19 20 21 22 23 24	1.1.8 1.1.9 <b>Occupati</b>	<ul> <li>Do not offer the following as diagnostic tests for asthma:</li> <li>skin prick tests to aeroallergens</li> <li>serum total and specific IgE</li> <li>peripheral blood eosinophil count</li> <li>exercise challenge (to adults aged 17 and over). [2017]</li> <li>Use skin prick tests to aeroallergens or specific IgE tests to identify triggers after a formal diagnosis of asthma has been made. [2017]</li> <li>onal asthma</li> <li>Check for possible occupational asthma by asking employed people with</li> </ul>	
<ol> <li>16</li> <li>17</li> <li>18</li> <li>19</li> <li>20</li> <li>21</li> <li>22</li> <li>23</li> <li>24</li> <li>25</li> </ol>	1.1.8 1.1.9 <b>Occupati</b>	<ul> <li>Do not offer the following as diagnostic tests for asthma:</li> <li>skin prick tests to aeroallergens</li> <li>serum total and specific IgE</li> <li>peripheral blood eosinophil count</li> <li>exercise challenge (to adults aged 17 and over). [2017]</li> <li>Use skin prick tests to aeroallergens or specific IgE tests to identify triggers after a formal diagnosis of asthma has been made. [2017]</li> <li>onal asthma</li> <li>Check for possible occupational asthma by asking employed people with suspected new-onset asthma, or established asthma that is poorly</li> </ul>	

1		<ul> <li>Are symptoms better when on holiday<sup>1</sup>?</li> </ul>
2		
3		Make sure all answers are recorded for later review. [2017]
4	1.1.11	Refer people with suspected occupational asthma to an occupational
5		asthma specialist. [2017]
6	1.2	Diagnosing asthma in young children
7	1.2.1	For children under 5 with suspected asthma, treat symptoms based on
8		observation and clinical judgement, and review the child on a regular
9		basis (see section 1.8). If they still have symptoms when they reach
10		5 years, carry out objective tests (see <u>section 1.3</u> and <u>algorithm B</u> ). <b>[2017]</b>
10		by years, early out objective tests (see <u>section 1.5</u> and <u>algorithm b</u> ). [2011]
11	1.2.2	If a child is unable to perform objective tests when they are aged 5:
12		<ul> <li>continue to treat based on observation and clinical judgement</li> </ul>
13		<ul> <li>try doing the tests again every 6 to 12 months until satisfactory results</li> </ul>
14		are obtained
15		consider referral for specialist assessment if the child repeatedly cannot
16		perform objective tests and is not responding to treatment. [2017]
17	1.3	Objective tests for diagnosing asthma in adults, young
18		people and children aged 5 and over
19	See also <u>t</u>	table 1 for a summary of objective test threshold levels.
20	Diagnost	ic hubs
21	1.3.1	Those responsible for planning diagnostic service support to primary care
22		(for example, clinical commissioning groups) should consider establishing
23		asthma diagnostic hubs to achieve economies of scale and improve the
24		practicality of implementing the recommendations in this guideline. [2017]
24		practicality of implementing the recommendations in this guideline. [2017]

<sup>&</sup>lt;sup>1</sup> 'Holiday' here means any longer time away from work than usual breaks at weekends or between shifts.

1	Airway in	flammation measures
2	Fractiona	l exhaled nitric oxide
3	1.3.2	Offer a FeNO test to adults (aged 17 and over) if a diagnosis of asthma is
4		being considered. Regard a FeNO level of 40 parts per billion (ppb) or
5		more as a positive test. <b>[2017]</b>
6	1.3.3	Consider a FeNO test in children and young people (aged 5 to 16) <sup>2</sup> if
7		there is diagnostic uncertainty after initial assessment and they have
8		either:
9		<ul> <li>normal spirometry or</li> </ul>
10		• obstructive spirometry with a negative bronchodilator reversibility (BDR)
11		test.
12		
13		Regard a FeNO level of 35 ppb or more as a positive test. [2017]
14	1.3.4	Be aware that a person's current smoking status can lower FeNO levels
15		both acutely and cumulatively. However, a high level remains useful in
16		supporting a diagnosis of asthma. [2017]
17	Lung fun	ction tests
18	Spiromet	ry
19	1.3.5	Offer spirometry to adults, young people and children aged 5 and over if a
20		diagnosis of asthma is being considered. Regard a forced expiratory
21		volume in 1 second/forced vital capacity (FEV1/FVC) ratio of less than
22		70% (or below the lower limit of normal if this value is available) as a
23		positive test for obstructive airway disease (obstructive spirometry).
24		[2017]

<sup>&</sup>lt;sup>2</sup> Children at the lower end of the age range may not be able to do the FeNO test adequately. In these cases, apply the principles in <u>recommendation 1.2.2</u>.

1	Bronchoo	lilator reversibility
2	1.3.6	Offer a BDR test to adults (aged 17 and over) with obstructive spirometry
3		(FEV1/FVC ratio less than 70%). Regard an improvement in FEV1 of 12% $$
4		or more, together with an increase in volume of 200 ml or more, as a
5		positive test. [2017]
6	1.3.7	Consider a BDR test in children and young people (aged 5 to 16) with
7		obstructive spirometry (FEV1/FVC ratio less than 70%). Regard an
8		improvement in FEV1 of 12% or more as a positive test. [2017]
9	Peak exp	iratory flow variability
10	1.3.8	Monitor peak flow variability for 2 to 4 weeks in adults (aged 17 and over)
11		if there is diagnostic uncertainty after initial assessment and a FeNO test
12		and they have either:
13		<ul> <li>normal spirometry or</li> </ul>
14		<ul> <li>obstructive spirometry, reversible airways obstruction (positive BDR)</li> </ul>
15		but a FeNO level of 39 ppb or less.
16		
17		Regard a value of more than 20% variability as a positive test. [2017]
18	1.3.9	Consider monitoring peak flow variability for 2 to 4 weeks in adults (aged
19		17 and over) if there is diagnostic uncertainty after initial assessment and
20		they have:
21		obstructive spirometry and
22		<ul> <li>irreversible airways obstruction (negative BDR) and</li> </ul>
23		<ul> <li>a FeNO level between 25 and 39 ppb.</li> </ul>
24		
25		Regard a value of more than 20% variability as a positive test. [2017]
26	1.3.10	Monitor peak flow variability for 2 to 4 weeks in children and young people
27		(aged 5 to 16) if there is diagnostic uncertainty after initial assessment
28		and a FeNO test and they have either:

1		<ul> <li>normal spirometry or</li> </ul>
2		• obstructive spirometry, irreversible airways obstruction (negative BDR)
3		and a FeNO level of 35 ppb or more.
4		
5		Regard a value of more than 20% variability as a positive test. [2017]
6	Airway h	yperreactivity measures
7	Direct br	onchial challenge test with histamine or methacholine
8	1.3.11	Offer a direct bronchial challenge test with histamine or methacholine <sup>3</sup> to
9		adults (aged 17 and over) if there is diagnostic uncertainty after a normal
10		spirometry and either a:
11		• FeNO level of 40 ppb or more and no variability in peak flow readings
12		or
13		• FeNO level of 39 ppb or less with variability in peak flow readings.
14		
15		Regard a PC20 value of 8 mg/ml or less as a positive test. [2017]
16	1.3.12	Consider a direct bronchial challenge test with histamine or methacholine <sup>3</sup>
17		in adults (aged 17 and over) with:
18		<ul> <li>obstructive spirometry without bronchodilator reversibility and</li> </ul>
19		<ul> <li>a FeNO level between 25 and 39 ppb and</li> </ul>
20		• no variability in peak flow readings (less than 20% variability over 2 to
21		4 weeks).
22		
23		Regard a PC20 value of 8 mg/ml or less as a positive test. [2017]
24	1.3.13	If a direct bronchial challenge test with histamine or methacholine is
25		unavailable, suspect asthma and review the diagnosis after treatment, or

<sup>&</sup>lt;sup>3</sup> At the time of publication (November 2017), histamine and methacholine did not have UK marketing authorisation for this use. The healthcare professional should follow relevant professional guidance, taking full responsibility for the decision to use this test. Informed consent should be obtained and documented. See the General Medical Council's <u>Prescribing guidance</u>: <u>prescribing unlicensed</u> <u>medicines</u> for further information.

1 2		refer to a centre with access to a histamine or methacholine challenge test. <b>[2017]</b>
3	Diagnosi	s in children and young people aged 5 to 16
4	See also <u>a</u>	algorithm B for objective tests in young people and children aged 5 to 16.
5 6	1.3.14	Diagnose asthma in children and young people (aged 5 to 16) if they have symptoms suggestive of asthma and:
7 8		<ul> <li>a FeNO level of 35 ppb or more and positive peak flow variability or</li> <li>obstructive spirometry and positive bronchodilator reversibility. [2017]</li> </ul>
9 10	1.3.15	Suspect asthma in children and young people (aged 5 to 16) if they have symptoms suggestive of asthma and:
<ol> <li>11</li> <li>12</li> <li>13</li> <li>14</li> <li>15</li> <li>16</li> <li>17</li> <li>18</li> <li>19</li> <li>20</li> <li>21</li> </ol>		<ul> <li>a FeNO level of 35 ppb or more with normal spirometry and negative peak flow variability, or</li> <li>a FeNO level of 35 ppb or more with obstructive spirometry but negative bronchodilator reversibility and no variability in peak flow readings, or</li> <li>normal spirometry, a FeNO level of 34 ppb or less and positive peak flow variability.</li> <li>Do not rule out other diagnoses if symptom control continues to remain poor after treatment. Review the diagnosis after 6 weeks by repeating any abnormal tests and reviewing symptoms. [2017]</li> </ul>
22 23 24	1.3.16	Refer children and young people (aged 5 to 16) for specialist assessment if they have obstructive spirometry, negative bronchodilator reversibility and a FeNO level of 34 ppb or less. <b>[2017]</b>
25 26 27 28	1.3.17	Consider alternative diagnoses and referral for specialist assessment in children and young people (aged 5 to 16) if they have symptoms suggestive of asthma but normal spirometry, a FeNO level of 34 ppb or less and negative peak flow variability. <b>[2017]</b>

1	Diagnosi	s in adults aged 17 and over
2	See also a	algorithm C for objective tests in adults aged 17 and over.
3 4	1.3.18	Diagnose asthma in adults (aged 17 and over) if they have symptoms suggestive of asthma and:
5 6 7 8 9 10 11		<ul> <li>a FeNO level of 40 ppb or more with either positive bronchodilator reversibility or positive peak flow variability or bronchial hyperreactivity, or</li> <li>a FeNO level between 25 and 39 ppb and a positive bronchial challenge test, or</li> <li>positive bronchodilator reversibility and positive peak flow variability irrespective of FeNO level. [2017]</li> </ul>
12 13	1.3.19	Suspect asthma in adults (aged 17 and over) with symptoms suggestive of asthma, obstructive spirometry and:
14 15 16 17 18 19 20 21 22 23		<ul> <li>negative bronchodilator reversibility, and either a FeNO level of 40 ppb or more, or a FeNO level between 25 and 39 ppb and positive peak flow variability, or</li> <li>positive bronchodilator reversibility, a FeNO level between 25 and 39 ppb and negative peak flow variability.</li> <li>Do not rule out other diagnoses if symptom control continues to remain poor after treatment. Review the diagnosis after 6 to 10 weeks by repeating spirometry and objective measures of asthma control and reviewing symptoms. [2017]</li> </ul>
24 25	1.3.20	Consider alternative diagnoses, or referral for a second opinion, in adults (aged 17 and over) with symptoms suggestive of asthma and:
26 27 28 29		<ul> <li>a FeNO level below 40 ppb, normal spirometry and positive peak flow variability, or</li> <li>a FeNO level of 40 ppb or more but normal spirometry, negative peak flow variability, and negative bronchial challenge test, or</li> </ul>

1		obstructive spirometry with bronchodilator reversibility, but a FeNO
2		level below 25 ppb, and negative peak flow variability, <b>or</b>
3		• positive peak flow variability but normal spirometry, a FeNO level below
4		40 ppb, and a negative bronchial challenge test, <b>or</b>
5		obstructive spirometry with negative bronchodilator reversibility, a
6		FeNO level below 25 ppb, and negative peak flow variability (if
7		measured). <b>[2017]</b>
8	Diagnosi	s in people who are unable to perform an objective test
0	Diagnosi	s in people who are unable to perform an objective test
9	For youn	g children who cannot perform objective tests, see <u>section 1.2</u> .
10	1.3.21	If an adult, young person or child with symptoms suggestive of asthma
11		cannot perform a particular test, try to perform at least 2 other objective
12		tests. Diagnose suspected asthma based on symptoms and any positive
13		objective test results. [2017]
14	Good cli	nical practice in asthma diagnosis
15	1.3.22	Record the basis for a diagnosis of asthma in a single entry in the
16		person's medical records, alongside the coded diagnostic entry. [2017]
17	1.4	Diagnostic summary
17	1.4	Diagnostic Summary
18	The follow	ving algorithms have been produced that summarise clinical assessment
19	and object	tive testing for asthma. Table 1 summarises the objective test threshold
20	levels.	


1 Table 1 Positive test thresholds for objective tests for adults, young people

#### 2 and children (aged 5 and over)

Test	Population	Positive result
FeNO	Adults	40 ppb or more
	Children and young people	35 ppb or more
Obstructive spirometry	Adults, young people and children	FEV1/FVC ratio less than 70% (or below the lower limit of normal if this value is available)
Bronchodilator reversibility (BDR) test	Adults	Improvement in FEV1 of 12% or more and increase in volume of 200 ml or more
	Children and young people	Improvement in FEV1 of 12% or more
Peak flow variability	Adults, young people and children	Variability over 20%
Direct bronchial challenge	Adults	PC20 of 8 mg/ml or less
test with histamine or methacholine	Children and young people	n/a
Abbreviations: FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PC20, provocative concentration of methacholine causing a 20% fall in FEV1.		


#### 3 Algorithm A Initial clinical assessment for adults, young people and children

4 with suspected asthma



- 1 2
- A full size downloadable PDF version is available in tools and resources


#### 1 Algorithm B Objective tests for asthma in children and young people aged



3

4

A full size downloadable PDF version is available in tools and resources



#### 1 Algorithm C Objective tests for asthma in adults aged 17 and over

- 3 A full size downloadable PD
  - A full size downloadable PDF version is available in tools and resources

## 4 1.5 Principles of pharmacological treatment

5 1.5.1 Take into account the possible reasons for <u>uncontrolled asthma</u>, before
6 starting or adjusting medicines for asthma in adults, young people and
7 children. These may include:

8	alternative diagnoses
9	lack of adherence
10	suboptimal inhaler technique
11	<ul> <li>smoking (active or passive)</li> </ul>
12	occupational exposures
13	psychosocial factors
14	• seasonal or environmental factors. [2017]

1 2 3	1.5.2	After starting or adjusting medicines for asthma, review the response to treatment in 4 to 8 weeks (see <u>section 1.14</u> on monitoring asthma control). [2017]
4 5 6	1.5.3	If inhaled corticosteroid (ICS) maintenance therapy is needed, offer regular daily ICS rather than intermittent or 'when required' ICS therapy. [2017]
7 8	1.5.4	Adjust the <u>dose of ICS</u> maintenance therapy over time, aiming for the lowest dose required for effective asthma control. <b>[2017]</b>
9	1.5.5	Ensure that a person with asthma can use their inhaler device:
10 11		<ul> <li>at any asthma review, either routine or unscheduled</li> <li>whenever a new type of device is supplied. [2017]</li> </ul>
12	1.6	Pharmacological treatment pathway for adults (aged
13		17 and over)
		<b>17 and over)</b> This section is for people with newly diagnosed asthma or asthma that is uncontrolled on their current treatment. Where the recommendations represent a change from traditional clinical practice, people whose asthma is well controlled on their current treatment should not have their treatment changed purely to follow this guidance.
13 14 15 16 17	1.6.1	This section is for people with newly diagnosed asthma or asthma that is uncontrolled on their current treatment. Where the recommendations represent a change from traditional clinical practice, people whose asthma is well controlled on their current treatment should not have their
13 14 15 16 17 18 19	1.6.1 1.6.2	This section is for people with newly diagnosed asthma or asthma that is uncontrolled on their current treatment. Where the recommendations represent a change from traditional clinical practice, people whose asthma is well controlled on their current treatment should not have their treatment changed purely to follow this guidance. Offer a short-acting beta <sub>2</sub> agonist (SABA) as reliever therapy to adults

1 2 3 4		<ul> <li>symptoms at presentation that clearly indicate the need for maintenance therapy (for example, asthma-related symptoms 3 times a week or more, or causing waking at night) or</li> <li>asthma that is uncontrolled with a SABA alone. [2017]</li> </ul>
5 6 7 8	1.6.4	If asthma is uncontrolled in adults (aged 17 and over) on a low dose of ICS as maintenance therapy, offer a leukotriene receptor antagonist (LTRA) in addition to the ICS and review the response to treatment in 4 to 8 weeks. <b>[2017]</b>
9 10 11 12	1.6.5	If asthma is uncontrolled in adults (aged 17 and over) on a low dose of ICS and an LTRA as maintenance therapy, offer a long-acting beta <sub>2</sub> agonist (LABA) in combination with the ICS, and review LTRA treatment as follows:
13 14		<ul> <li>discuss with the person whether or not to continue LTRA treatment</li> <li>take into account the degree of response to LTRA treatment. [2017]</li> </ul>
15 16 17 18	1.6.6	If asthma is uncontrolled in adults (aged 17 and over) on a low dose of ICS and a LABA, with or without an LTRA, as maintenance therapy, offer to change the person's ICS and LABA maintenance therapy to a <u>MART</u> regimen with a low maintenance ICS dose. <b>[2017]</b>
19 20 21 22 23	1.6.7	If asthma is uncontrolled in adults (aged 17 and over) on a MART regimen with a low maintenance ICS dose, with or without an LTRA, consider increasing the ICS to a moderate maintenance dose (either continuing on a MART regimen or changing to a fixed-dose of an ICS and a LABA, with a SABA as a reliever therapy). <b>[2017]</b>
24 25 26	1.6.8	If asthma is uncontrolled in adults (aged 17 and over) on a moderate maintenance ICS dose with a LABA (either as MART or a fixed-dose regimen), with or without an LTRA, consider:
27 28 29		<ul> <li>increasing the ICS to a high maintenance dose (this should only be offered as part of a fixed-dose regimen, with a SABA used as a reliever therapy) or</li> </ul>

1 2		<ul> <li>a trial of an additional drug (for example, a long-acting muscarinic receptor antagonist or theophylline) or</li> </ul>
3 4		<ul> <li>seeking advice from a healthcare professional with expertise in asthma.</li> <li>[2017]</li> </ul>
5	1.7	Pharmacological treatment pathway for children and
6		young people aged 5 to 16
7 8 9 10 11 12		This section is for children and young people with newly diagnosed asthma or asthma that is uncontrolled on their current treatment. Where the recommendations represent a change from traditional clinical practice, children and young people whose asthma is well controlled on their current treatment should not have their treatment changed purely to follow guidance.
13 14	1.7.1	Offer a SABA as reliever therapy to children and young people (aged 5 to 16) with newly diagnosed asthma. <b>[2017]</b>
15 16 17	1.7.2	For children and young people (aged 5 to 16) with asthma who have infrequent, short-lived wheeze and normal lung function, consider treatment with SABA reliever therapy alone. <b>[2017]</b>
18 19	1.7.3	Offer a paediatric low dose of an ICS as the first-line maintenance therapy to children and young people (aged 5 to 16) with:
20 21 22 23		<ul> <li>symptoms at presentation that clearly indicate the need for maintenance therapy (for example, asthma-related symptoms 3 times a week or more, or causing waking at night) or</li> <li>asthma that is uncontrolled with a SABA alone. [2017]</li> </ul>
24 25	1.7.4	If asthma is uncontrolled in children and young people (aged 5 to 16) on a paediatric low dose of ICS as maintenance therapy, consider an LTRA <sup>4</sup> in

<sup>&</sup>lt;sup>4</sup> At the time of publication (November 2017), not all LTRAs have a UK marketing authorisation for use in children and young people aged under 18 for this indication.

1 2		addition to the ICS and review the response to treatment in 4 to 8 weeks. [2017]
3	1.7.5	If asthma is uncontrolled in children and young people (aged 5 to 16) on a
4		paediatric low dose of ICS and an LTRA as maintenance therapy,
5		consider stopping the LTRA and starting a LABA <sup>5</sup> in combination with the
6		ICS. [2017]
7	1.7.6	If asthma is uncontrolled in children and young people (aged 5 to 16) on a
8		paediatric low dose of ICS and a LABA as maintenance therapy, consider
9		changing their ICS and LABA maintenance therapy to a MART regimen <sup>6</sup>
10		with a paediatric low maintenance ICS dose. Ensure that the child or
11		young person is able to understand and comply with the MART regimen.
12		[2017]
13	1.7.7	If asthma is uncontrolled in children and young people (aged 5 to 16) on a
14		MART regimen <sup>6</sup> with a paediatric low maintenance ICS dose, consider
15		increasing the ICS to a paediatric moderate maintenance dose (either
16		continuing on a MART regimen or changing to a fixed-dose of an ICS and
17		a LABA, with a SABA as a reliever therapy). [2017]
18	1.7.8	If asthma is uncontrolled in children and young people (aged 5 to 16) on a
19		paediatric moderate maintenance ICS dose with LABA (either as MART <sup>6</sup>
20		or a fixed-dose regimen), consider seeking advice from a healthcare
21		professional with expertise in asthma and consider either:
22		• increasing the ICS dose to paediatric high maintenance dose (only as
23		part of a fixed-dose regimen, with a SABA used as a reliever therapy)
23 24		or
<u>-</u>		

<sup>&</sup>lt;sup>5</sup> At the time of publication (November 2017), not all LABAs have a UK marketing authorisation for use in children and young people aged under 18 for this indication.

<sup>&</sup>lt;sup>6</sup> At the time of publication (November 2017), MART regimens did not have a UK marketing authorisation for use in children and young people (aged under 12) for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's <u>Prescribing guidance</u>: prescribing unlicensed medicines for further information.

1		• a trial of an additional drug (for example, theophylline). [2017]
2	1.8	Pharmacological treatment pathway for children under 5
3 4 5 6		It can be difficult to confirm asthma diagnosis in young children, therefore these recommendations apply to children with suspected or confirmed asthma. Asthma diagnosis should be confirmed when the child is able to undergo objective tests (see section 1.2).
7 8 9 10 11 12		This section is for children under 5 with newly suspected or confirmed asthma, or with asthma symptoms that are uncontrolled on their current treatment. Where the recommendations represent a change from traditional clinical practice, children whose asthma is well controlled on their current treatment should not have their treatment changed purely to follow this guidance.
13 14 15	1.8.1	Offer a SABA as reliever therapy to children under 5 with <u>suspected</u> <u>asthma</u> . This should be used for symptom relief alongside all maintenance therapy. <b>[2017]</b>
16 17	1.8.2	Consider an 8-week trial of a paediatric moderate dose of an ICS in children under 5 with:
18 19 20 21		<ul> <li>symptoms at presentation that clearly indicate the need for maintenance therapy (for example, asthma-related symptoms 3 times a week or more, or causing waking at night) or</li> <li>suspected asthma that is uncontrolled with a SABA alone. [2017]</li> </ul>
22 23	1.8.3	After 8 weeks, stop ICS treatment and continue to monitor the child's symptoms:
24 25 26 27 28		<ul> <li>if symptoms did not resolve during the trial period, review whether an alternative diagnosis is likely</li> <li>if symptoms resolved then reoccurred within 4 weeks of stopping ICS treatment, restart the ICS at a paediatric low dose as first-line maintenance therapy</li> </ul>

1 2 3		<ul> <li>if symptoms resolved but reoccurred beyond 4 weeks after stopping ICS treatment, repeat the 8-week trial of a paediatric moderate dose of ICS. [2017]</li> </ul>
4 5 6	1.8.4	If suspected asthma is uncontrolled in children under 5 on a paediatric low dose of ICS as maintenance therapy, consider an LTRA <sup>7</sup> in addition to the ICS. <b>[2017]</b>
7 8 9 10	1.8.5	If suspected asthma is uncontrolled in children under 5 on a paediatric low dose of ICS and an LTRA as maintenance therapy, stop the LTRA and refer the child to a healthcare professional with expertise in asthma for further investigation and management. <b>[2017]</b>
11	1.9	Adherence
12 13	1.9.1	For guidance on managing non-adherence to medicines in people with asthma, see the NICE guideline on medicines adherence. [2017]
14	1.10	Self-management
15 16 17 18	1.10.1	Offer an asthma self-management programme, comprising a written personalised action plan and education, to adults, young people and children aged 5 and over with a diagnosis of asthma (and their families or carers if appropriate). <b>[2017]</b>
19 20 21 22 23	1.10.2	Within a self-management programme, offer an increased dose of ICS for 7 days to adults (aged 17 and over) who are using an ICS in a single inhaler, when asthma control deteriorates. Clearly outline in the person's asthma action plan how and when to do this, and what to do if symptoms do not improve. When increasing ICS treatment:
24 25		<ul> <li>consider quadrupling the regular ICS dose</li> <li>do not exceed the maximum licensed daily dose. [2017]</li> </ul>

<sup>&</sup>lt;sup>7</sup> At the time of publication (November 2017), not all LTRAs have a UK marketing authorisation for use in children and young people aged under 18 for this indication.

1	1.10.3	For children and young people aged 5 to 16 with a diagnosis of asthma,
2		include advice in their self-management plan on contacting a healthcare
3		professional for a review, if their asthma control deteriorates (see also
4		section 1.13 on monitoring asthma control). Encourage consistent ICS
5		use to prevent deterioration and explain that there is no evidence of
6		clinical benefit from increased doses of ICS. For people who have not
7		maintained consistent ICS use, restarting ICS and taking it regularly may
8		help them to regain control of their asthma. [2020]

9 1.10.4 Consider an asthma self-management programme, comprising a written
10 personalised action plan and education, for the families or carers of
11 children under 5 with suspected or confirmed asthma. [2017]

To find out why the committee made the 2020 recommendation on selfmanagement and removed the 2017 recommendation on increasing ICS treatment within a self-management programme in children and young people and how this might affect practice, see <u>rationale and impact</u>.

12	1.11	Decreasing maintenance therapy
13	1.11.1	Consider decreasing maintenance therapy when a person's asthma has
14		been controlled with their current maintenance therapy for at least
15		3 months. [2017]
16	1.11.2	Discuss with the person (or their family or carer if appropriate) the
17		potential risks and benefits of decreasing maintenance therapy. [2017]
18	1.11.3	When reducing maintenance therapy:
19		• Stop or reduce dose of medicines in an order that takes into account
20		the clinical effectiveness when introduced, side effects and the person's
21		preference.
22		Only consider stopping ICS treatment completely for people who are
23		using low dose ICS alone as maintenance therapy and are symptom
24		free. [2017]

1 2 3 4	1.11.4	Agree with the person (or their family or carer if appropriate) how the effects of decreasing maintenance therapy will be monitored and reviewed, including self-monitoring and a follow-up with a healthcare professional. [2017]
5 6	1.11.5	Review and update the person's asthma action plan when decreasing maintenance therapy. <b>[2017]</b>
7	1.12	Risk stratification
8 9 10 11 12	1.12.1	Consider using <u>risk stratification</u> to identify people with asthma who are at increased risk of poor outcomes, and use this information to optimise their care. Base risk stratification on factors such as non-adherence to asthma medicines, psychosocial problems and repeated episodes of unscheduled care for asthma. <b>[2017]</b>
13	1.13	Monitoring asthma control
14	1.13.1	Monitor asthma control at every review. If control is suboptimal:
15		• confirm the person's adherence to prescribed treatment in line with the
16 17 18 19 20 21		<ul> <li>recommendations on <u>assessing adherence</u> in the NICE guideline on medicines adherence</li> <li>review the person's inhaler technique</li> <li>review if treatment needs to be changed</li> <li>ask about occupational asthma (see <u>recommendation 1.1.10</u>) and/or other triggers, if relevant. [2017]</li> </ul>
17 18 19 20	1.13.2	<ul> <li>medicines adherence</li> <li>review the person's inhaler technique</li> <li>review if treatment needs to be changed</li> <li>ask about occupational asthma (see recommendation 1.1.10) and/or</li> </ul>
17 18 19 20 21 22 23	1.13.2	<ul> <li>medicines adherence</li> <li>review the person's inhaler technique</li> <li>review if treatment needs to be changed</li> <li>ask about occupational asthma (see recommendation 1.1.10) and/or other triggers, if relevant. [2017]</li> <li>Consider using a validated questionnaire (for example, the Asthma Control Questionnaire or Asthma Control Test) to monitor asthma control</li> </ul>

1	1.13.5	Consider FeNO measurement as an option to support asthma	
2		management in people who are symptomatic despite using inhaled	
3		corticosteroids. (This recommendation is from NICE's diagnostics	
4		guidance on measuring fractional exhaled nitric oxide concentration in	
5		<u>asthma</u> .) <b>[2017]</b>	
6	1.13.6	Do not use challenge testing to monitor asthma control. [2017]	
7	1.13.7	Observe and give advice on the person's inhaler technique:	
8		• at every consultation relating to an asthma attack, in all care settings	
9		when there is deterioration in asthma control	
10		when the inhaler device is changed	
11		<ul> <li>at every annual review</li> </ul>	
12		• if the person asks for it to be checked. [2017]	
	-	1. A	
13	Terms u	sed in this guideline	
14	This section	on defines terms that have been used in a particular way for this guideline.	
15	For other	definitions see the <u>NICE glossary</u> .	
16	Expirator	y polyphonic wheeze	
17	A wheeze	is a continuous, whistling sound produced in the airways during breathing.	
18	It is caused by narrowing or obstruction in the airways. An expiratory polyphonic		
19	wheeze has multiple pitches and tones heard over different areas of the lung when		
20	the persor	n breathes out.	
21	ICS dose	S	
22	ICS doses	and their pharmacological strengths vary across different formulations. In	
23	general, people with asthma should use the smallest doses of ICS that provide		
24	optimal co	ontrol for their asthma, in order to reduce the risk of side effects.	
25	For adults	aged 17 and over:	
26	<ul> <li>less that</li> </ul>	an or equal to 400 micrograms budesonide or equivalent would be	
27	conside	ered a low dose	

- more than 400 micrograms to 800 micrograms budesonide or equivalent would be
   considered a moderate dose
- more than 800 micrograms budesonide or equivalent would be considered a high dose.
- 5 For children and young people aged 16 and under:
- less than or equal to 200 micrograms budesonide or equivalent would be
  considered a paediatric low dose
- 8 more than 200 micrograms to 400 micrograms budesonide or equivalent would be
  9 considered a paediatric moderate dose
- more than 400 micrograms budesonide or equivalent would be considered a
  paediatric high dose.

#### 12 **MART**

- 13 Maintenance and reliever therapy (MART) is a form of combined ICS and LABA
- 14 treatment in which a single inhaler, containing both ICS and a fast-acting LABA, is
- 15 used for both daily maintenance therapy and the relief of symptoms as required.
- 16 MART is only available for ICS and LABA combinations in which the LABA has a
- 17 fast-acting component (for example, formoterol).

#### 18 **Objective test to diagnose asthma**

Tests carried out to help determine whether a person has asthma, the results of
which are not based on the person's symptoms, for example, tests to measure lung
function or evidence of inflammation. There is no single objective test to diagnose
asthma.

#### 23 **Risk stratification**

- 24 Risk stratification is a process of categorising a population by their relative likelihood
- 25 of experiencing certain outcomes. In the context of this guideline, risk stratification
- 26 involves categorising people with asthma by their relative likelihood of experiencing
- 27 negative clinical outcomes (for example, severe exacerbations or hospitalisations).
- 28 Factors including non-adherence to asthma medicines, psychosocial problems and
- 29 repeated episodes of unscheduled care can be used to guide risk stratification.

- 1 Once the population is stratified, the delivery of care for the population can be
- 2 targeted with the aim of improving the care of the strata with the highest risk.

#### 3 Suspected asthma

- 4 Suspected asthma describes a potential diagnosis of asthma based on symptoms
- 5 and response to treatment that has not yet been confirmed with objective tests.

#### 6 **Uncontrolled asthma**

- 7 Uncontrolled asthma describes asthma that has an impact on a person's lifestyle or
- 8 restricts their normal activities. Symptoms such as coughing, wheezing, shortness of
- 9 breath and chest tightness associated with uncontrolled asthma can significantly
- 10 decrease a person's quality of life and may lead to a medical emergency.
- 11 Questionnaires are available that can be quantify this.
- 12 This guideline uses the following pragmatic thresholds to define uncontrolled
- 13 asthma:
- 3 or more days a week with symptoms or
- 3 or more days a week with required use of a SABA for symptomatic relief **or**
- 1 or more nights a week with awakening due to asthma.

## 17 **Putting this guideline into practice**

18 NICE is recommending objective testing with spirometry and FeNO for most people 19 with suspected asthma. This is a significant enhancement to current practice, which 20 will take the NHS some time to implement, with additional infrastructure and training 21 needed in primary care. New models of care, being developed locally, could offer the 22 opportunity to implement these recommendations. This may involve establishing 23 diagnostic hubs to make testing efficient and affordable. They will be able to draw on 24 the positive experience of NICE's primary care pilot sites, which trialled the use of FeNO. 25

- 26 The investment and training required to implement the new guidance will take time.
- 27 In the meantime, primary care services should implement what they can of the new

- 1 guidelines, using currently available approaches to diagnosis until the infrastructure
- 2 for objective testing is in place.
- 3 NICE has produced tools and resources to help you put this guideline into practice.
- 4 Adoption support resource
- 5 <u>Resource impact report</u>
- 6 <u>Resource impact templates</u>

## 7 Recommendations for research

- 8 The 2017 guideline committee made the following recommendations for research on
- 9 diagnosing and monitoring asthma and for managing chronic asthma. The
- 10 committee's full set of research recommendations is detailed in the 2017 full
- 11 guideline on asthma: diagnosis and monitoring and the 2017 full guideline on chronic
- 12 <u>asthma management</u>.
- 13 As part of the 2020 update, the guideline committee made 1 new research
- 14 recommendation on managing asthma within a personalised asthma plan for
- 15 children and young people.

## 16 **Diagnosing and monitoring asthma**

#### 17 **1** Diagnosing asthma in children and young people aged 5 to 16

- 18 What is the acceptability and diagnostic accuracy of objective tests that could be
- 19 used to comprise a diagnostic pathway for asthma in children and young people
- aged 5 to 16 (for example, exercise challenge, direct bronchial challenge with
- 21 histamine or methacholine, indirect bronchial challenge with mannitol and peripheral
- 22 blood eosinophil count)? [2017]

#### 23 Why this is important

- Asthma is a common condition, diagnosed in nearly 1 in 10 children. There are no
- 25 validated and reliable objective criteria for diagnosing asthma, so the vast majority of
- 26 asthma diagnoses are currently based on symptoms and signs. However, symptoms
- and signs consistent with a diagnosis of asthma are not specific to the condition and
- 28 can be present in other illnesses. This diagnostic uncertainty results in many children

- 1 being incorrectly diagnosed with asthma, and many children with asthma in whom
- 2 the diagnosis is delayed or missed. A single objective measure, or set of objective
- 3 measures, that can be performed easily in non-specialist clinical settings (although it
- 4 is noted that challenge tests need to be performed in specialist settings) will help
- 5 improve diagnostic certainty and reduce the proportion of children treated
- 6 inappropriately for asthma. This would ensure that children with the condition are
- 7 identified and treated early.

#### 8 2 Diagnosing asthma in adults (aged 17 and over)

- 9 What is the clinical and cost effectiveness of using an indirect bronchial challenge
- 10 test with mannitol to diagnose asthma in adults (aged 17 and over)? [2017]

#### 11 *Why this is important*

- 12 Chronic airway inflammation is associated with bronchial hyper-responsiveness,
- 13 which is integral to defining asthma. Bronchial challenge testing can help diagnose
- 14 asthma and assess response to inhaled corticosteroid therapy. It can also be used to
- 15 monitor asthma control, alongside assessing symptoms and lung function. It is
- 16 increasingly used in asthma management, although currently most tests are
- 17 performed only in specialised centres or research settings.
- 18 Indirect challenge tests with inhaled mannitol act via active inflammatory cells and
- 19 mediators, whereas direct challenge tests with inhaled histamine or methacholine act
- 20 directly on bronchial smooth muscle. Indirect challenge testing is more specific but
- 21 less sensitive than direct challenges.
- 22 Direct challenge testing may not identify a person whose asthma will respond to
- 23 inhaled corticosteroids. A positive result to an indirect challenge may reflect active
- 24 airway inflammation that is likely to respond to inhaled corticosteroid therapy.
- 25 Because a response to mannitol indicates active airway inflammation, identifying
- 26 non-responsiveness in treated patients may help demonstrate good asthma control
- 27 with inhaled corticosteroid therapy and identify people whose asthma is less likely to
- 28 deteriorate after a dose reduction.

- 1 Mannitol bronchial challenge testing is quicker and simpler than current direct tests
- 2 (which are generally confined to specialist respiratory centres), and uses a
- 3 standardised inhaler device, so is potentially more useful in primary care.

#### **4 3 Monitoring adherence to treatment**

- 5 What is the clinical and cost effectiveness of using electronic alert systems designed
- 6 to monitor and improve adherence with regular inhaled maintenance therapy in
- 7 people with asthma? [2017]

#### 8 Why this is important

- 9 Adherence with regular maintenance inhaled corticosteroids, on their own or in
- 10 combination with long-acting beta agonists, is of paramount importance to achieve
- 11 control of asthma and prevent asthma attacks. Published evidence in patients with
- 12 severe asthma suggests that at least 30% of patients are partially or non-adherent
- 13 with their prescribed medications, and the Royal College of Physicians' National
- 14 Review of Asthma Deaths (NRAD) demonstrated that poor adherence was
- 15 associated with 38% of asthma deaths.

#### 16 4 Monitoring inhaler technique

- 17 What is the current frequency and the current method being used to check the
- 18 inhaler technique of people with asthma? What is the optimal frequency and the best
- 19 method of checking inhaler technique to improve clinical outcomes for people with
- 20 asthma? [2017]

## 21 Why this is important

Knowing and understanding how to use an inhaler properly is the cornerstone of
asthma management and symptom control. There has been an increase in the types
of inhaler devices and the types of delivery system available. The various types of
drugs for asthma control are also available in different inhaler devices on their own
and in a combination of 2 drugs. It is therefore vital for patients to learn the proper
inhaler technique for their device to ensure optimum drug delivery to the lungs for
asthma control.

#### **5 Monitoring asthma control using tele-healthcare**

- 2 What is the long-term (more than 12 months) clinical and cost effectiveness of using
- 3 tele-healthcare as a means to monitor asthma control in adults, young people and
- 4 children? Methods of tele-healthcare can include telephone interview (with
- 5 healthcare professional involvement) and internet or smartphone-based monitoring
- 6 support (no healthcare professional involvement). [2017]

#### 7 Why this is important

- 8 Asthma outcomes have not improved in the past 15 years, and the personal and
- 9 economic costs of poor control are high. Computers and smartphones play an ever-
- 10 greater role in modern life, with a growing proportion of people using them regularly
- 11 for work, leisure, communication and information. The efficient use of distance
- 12 monitoring systems and the integration of new technologies into healthcare are
- 13 important for patients and for healthcare systems in terms of convenience, costs and
- 14 outcomes.

## 15 Managing chronic asthma

#### 16 **1** Increasing the dose of ICS within a personalised asthma plan for children

#### 17 and young people

- 18 For children and young people with asthma that is managed in primary care, is there
- 19 an advantage to increasing the ICS dose when asthma control has deteriorated
- 20 compared with using the usual dose in a personalised asthma plan? [2020]
- 21 To find out why the committee made the research recommendation see <u>rationale</u>
- 22 and impact.

#### 23 **2 Starting asthma treatment**

- 24 In adults, young people and children with asthma who have not been treated
- 25 previously, is it more clinically and cost effective to start treatment with a reliever
- alone (a short-acting beta<sub>2</sub> agonist [SABA]) or with a reliever (a SABA) and
- 27 maintenance therapy (such as ICS)? Are there specific prognostic features that
- 28 indicate that one of these treatment options may be more appropriate for some
- 29 groups? **[2017]**

#### 1 Why this is important

2 Recently best practice has shifted from starting people with asthma on a SABA as a 3 reliever alone and starting maintenance therapy only if the person continues to have 4 persistent asthma symptoms, to starting people on a low dose inhaled corticosteroid 5 (ICS) as maintenance therapy alongside the SABA at the first instance. The 6 committee agree with this shift and have included consensus-based 7 recommendations in line with this pattern. However, the shift is not based on direct clinical evidence comparing these strategies for people with newly diagnosed 8 9 asthma. There is also little evidence to support the particular groups in which one 10 option or the other is more appropriate.

#### **3 Second-line maintenance therapy in children and young people (under 16)**

Is maintenance therapy more effective with a paediatric low dose of ICS plus a
leukotriene receptor antagonist (LTRA) or with a paediatric low dose of ICS plus a
long-acting beta<sub>2</sub> agonist (LABA) in the treatment of asthma in children and young
people (under 16) who have uncontrolled asthma on a paediatric low dose of ICS

16 alone? [2017]

## 17 Why this is important

There is a lack of evidence on managing asthma in children and young people under 16. Many of the recommendations for children and young people in this guideline were made using extrapolation from the adult evidence and the consensus of the guideline committee. The guideline committee would like to encourage more research in this age group. This particular question was prioritised because it affects the early stages of the treatment pathway and could have significant clinical and cost implications for managing asthma in this age group.

# 4 Additional maintenance therapy for asthma uncontrolled on a moderate dose of ICS plus LABA with or without LTRA

- 27 What is the clinical and cost effectiveness of offering additional maintenance therapy
- to adults, young people and children with asthma that is uncontrolled on a moderate
- 29 dose of ICS plus LABA with or without LTRA? [2017]

#### 1 Why this is important

2 The evidence is insufficient in quantity and quality to support strong

3 recommendations for the use of additional maintenance therapy beyond moderate
4 dose ICS plus LABA. The clinical evidence tends to favour the addition of a long-

5 acting muscarinic antagonist (LAMA) but the guideline committee did not consider

6 this to be conclusive, particularly because the addition of a LAMA is not cost

7 effective compared with treatment with a placebo. In current practice, the alternative

- 8 treatment options to adding a LAMA at this stage are increasing ICS dose to high,
- 9 addition of theophyllines or a course of oral steroids. Therefore, to truly understand
- 10 the cost effectiveness of LAMAs, a randomised controlled trial and health economic
- analysis taking into account the impact of LAMAs on oral steroid use and comparing
- 12 the addition of LAMAs to any alternative strategy (as opposed to just placebo) is
- 13 needed. The guideline committee felt the body of evidence, supported by consensus
- 14 agreement and current practice, was sufficient to weakly recommend the options of

15 ICS high dose plus LABA, addition of a LAMA or theophylline or seeking advice from

- 16 a healthcare professional with expertise in asthma. However, a study comparing
- 17 these various strategies would be critical for stronger recommendations or a more
- 18 specific order of options.

#### 19 **5 Decreasing pharmacological treatment**

20 In adults, young people and children with well-controlled asthma, what are the

- 21 objective measurements and prognostic factors that indicate that a decrease in
- regular maintenance treatment is appropriate? [2017]

#### 23 Why this is important

There is consensus within the guideline committee and across healthcare
professionals managing asthma that people with well-controlled asthma should not
remain on high dose or multiple preventer medicines for long periods of time.
However, there is little evidence available about which people might benefit most
from decreasing regular maintenance therapy. This guideline identified 3 studies

- attempting to answer this question but none of them included a sufficiently large
- 30 population, with suitable decrease in treatment throughout and assessment of
- 31 multiple prognostic markers.

#### 1 6 Improving adherence to asthma medication 2 What are the most clinically and cost-effective strategies to improve medicines 3 adherence in adults, young people and children with asthma who are non-adherent 4 to prescribed medicines? [2017] 5 Why this is important 6 There is a consensus within the guideline committee and across healthcare 7 professionals that medicines adherence is an important determinant of asthma 8 control, and that non-adherence is a common problem. However, there is a lack of 9 high-quality evidence on methods to improve adherence to asthma medicines. The 10 guideline identified a number of studies focusing on this question, but there was not 11 a strong body of evidence behind any specific intervention strategy. In addition, the 12 guideline committee had concerns about the applicability of studies that did not 13 report outcomes after a prolonged follow-up and studies that only used self-reported 14 measures to assess adherence. The guideline committee felt further that higherquality research is needed to recommend specific interventions for this common and 15 16 significant problem.

## 17 Rationale and impact

- 18 These sections briefly explain why the committee made the recommendations and
- 19 how they might affect practice. They link to details of the evidence and a full
- 20 description of the committee's discussion.

#### 21 Self-management

#### 22 Recommendation 1.10.3

#### 23 Why the committee changed the recommendations

- 24 The evidence for children and young people found that increasing the dose of
- 25 inhaled corticosteroid (ICS) did not show any benefits or harms compared to the
- 26 usual dose for reducing asthma exacerbations. It was limited to only 1 study with a
- 27 small number of participants who had a personalised action plan. The committee
- also looked at studies in adults, but agreed that the evidence was not applicable
- 29 because of the high average age of participants.

1 The 2017 guideline recommended that guadrupling the dose of ICS could be 2 considered within a self-management plan for children and young people whose 3 asthma is deteriorating. The guideline update committee agreed that this was based 4 on limited evidence, mostly in adults, and that the new evidence did not support this. 5 However, it also agreed that there wasn't any significant evidence to suggest that 6 increasing the dose of ICS is harmful compared to the usual dose. The committee 7 believe that increasing the dose of ICS within the licensed limit does not reduce child 8 growth. This is supported by the evidence, which showed that increasing the dose in 9 the short term did not result in a statistically significant decrease in child growth, 10 even though the study exceeded the licensed limit.

Therefore, the committee decided to remove the 2017 recommendation rather than
replacing it with a recommendation that prohibits increasing the dose of ICS.

13 The committee discussed the importance of a personalised action plan to guide 14 children and young people if their asthma worsens and to reassure them that they 15 are in control of their treatment. Children and young people who find that increasing 16 their dose of ICS is helpful when their asthma control worsens should be able to 17 continue to do this as an agreed strategy in their action plan. However, based on their experience the committee members agreed that it is important to review the 18 19 child or young person's self-management plan if their asthma control is deteriorating. 20 Reviews involve checking current medicines and inhaler technique, discussing any 21 factors that may be triggering symptoms, discussing adherence and education 22 needs, and reviewing their action plan. They should be carried out as needed, in 23 addition to annual review.

The committee also discussed the importance of an individualised approach for children and young people, because they have varied and changing support needs at different ages. Studies have shown that most child asthma deaths involve children who have frequent but mild symptoms that are not responding to their personalised action plan. This recommendation should help to ensure that these children and young people receive the support that they need if they start to have problems with their asthma control.

- 1 The committee agreed that further research is needed to give clearer guidance on
- 2 increasing the dose of ICS in children and young people within a self-management
- 3 plan and made a <u>research recommendation</u> to promote further research and inform
- 4 future practice.

#### 5 How the recommendations might affect practice

- 6 The recommendation will lead to an increase in the review of self-management
- 7 programmes for children and young people and reduce the variation in current
- 8 practice for this. The increase in resources needed for this is likely to be offset by a
- 9 reduction in the cost of treating asthma exacerbations.
- 10 Full details of the evidence and the committee's discussion are in evidence review:
- 11 increasing ICS treatment within supported self-management for children and young
- 12 <u>people</u>.
- 13 Return to recommendations

## 14 **Context**

- 15 Asthma is a chronic inflammatory respiratory disease. It can affect people of any
- 16 age, but often starts in childhood. Asthma is a variable disease which can change
- 17 throughout a person's life, throughout the year and from day to day. It is
- 18 characterised by attacks (also known as exacerbations) of breathlessness and
- 19 wheezing, with the severity and frequency of attacks varying from person to person.
- 20 The attacks are associated with variable airflow obstruction and inflammation within
- 21 the lungs, which if left untreated can be life-threatening, however with the
- 22 appropriate treatment can be reversible.
- In 2018 the Global Asthma report estimated that asthma affects 339 million people
  worldwide. It is the most common chronic condition to affect children, and in the UK
  approximately 5.4 million people (1.1 million children and 4.3 million adults) currently
  get treatment for asthma (Asthma UK).
- 27 The causes of asthma are not well understood. A number of risk factors are
- associated with the condition, often in combination. These influences can be genetic
- 29 (the condition clusters in families) and/or environmental (such as inhalation of

allergens or chemical irritants). Occupational causes of asthma in adults are often
 under-recognised.

#### 3 **Diagnosis and monitoring**

There is currently no gold standard test available to diagnose asthma; diagnosis is principally based on a thorough history taken by an experienced clinician. Studies of adults diagnosed with asthma suggest that up to 30% do not have clear evidence of asthma. Some may have had asthma in the past, but it is likely that many have been given an incorrect diagnosis. Conversely, other studies suggest that asthma may be underdiagnosed in some cases.

10 The diagnosis recommendations will improve patient outcomes and will be cost-

11 effective to the NHS in the long-term; NICE's cost impact assessment projects a

12 saving of approximately £12 million per year in England, before implementation

- 13 costs.
- 14 Initial clinical assessment should include questions about symptoms (wheezing,
- 15 cough, breathing and chest problems) and any personal or family history of allergies,
- 16 atopic disorders or asthma. Various tests can be used to support a diagnosis, but
- 17 there is no single test that can definitively diagnose asthma.
- 18 A number of methods and assessments are available to determine the likelihood of
- 19 asthma. These include measuring airflow obstruction (spirometry and peak flow) and
- 20 assessment of reversibility with bronchodilators, with both methods being widely
- 21 used in current clinical practice. However, normal results do not exclude asthma and
- 22 abnormal results do not always mean it is asthma, because they could be indicators
- 23 of other respiratory diseases or spurious readings.
- 24 Testing for airway inflammation is increasingly used as a diagnostic strategy in
- 25 clinical practice. This includes measuring fractional exhaled nitric oxide (FeNO).
- 26 Other diagnostic strategies include blood or skin prick tests to detect allergic
- 27 reactions to environmental influences, exercise tests to detect evidence of
- 28 bronchoconstriction, and measures of airway hyperreactivity such as
- 29 histamine/methacholine or mannitol challenge tests. However, it is debatable which

test or measure, or combination of them, is the most effective to accurately diagnoseasthma.

It is recognised that asthma control is suboptimal in many people with asthma. This
has an impact on their quality of life, their use of healthcare services and the
associated costs. Asthma control can be monitored by measuring airway obstruction
or inflammation and by using validated questionnaires, but the most effective
monitoring strategy is unclear.

## 8 Managing chronic asthma

9 The severity of asthma varies; some people have severe asthma that limits normal

10 activities, whereas others are able to lead a relatively normal life. The illness

11 fluctuates during the year and over time, so the level of treatment needs to be

12 tailored to the person's current level of asthma severity. Many people with asthma,

13 particularly children, seem to have fewer symptoms over time, and an important part

14 of management is decreasing treatment if asthma is well controlled.

15 There is no cure for asthma, so management focuses on reducing exposure to

16 known triggers if possible, relief of symptoms if there is airway narrowing, and

17 reduction in airway inflammation by regular preventive treatment. Adherence to

18 regular treatment reduces the risk of significant asthma attacks in most people with

19 asthma. The focus of asthma management in recent years has been on supporting

20 people with asthma and their healthcare professional to devise a personalised

21 treatment plan that is effective and relatively easy to implement.

## 22 The aims of this guideline

The guideline covers children under 5, children and young people aged 5 to 16, and adults aged 17 and over with suspected or diagnosed asthma. The guideline applies to all primary, secondary and community care settings in which NHS-funded care is provided for people with asthma.

27 The sections on diagnosing and monitoring asthma (sections 1.1 to 1.4 and 1.14)

28 aim to provide clear advice on effectively diagnosing people presenting with new

29 symptoms of suspected asthma and monitoring to ensure optimum asthma control. It

is not intended to be used to re-diagnose people who already have an asthma
 diagnosis.

- 3 The sections on managing chronic asthma (sections 1.5 to 1.13) aim to provide clear
- 4 advice for healthcare professionals and people with asthma to develop a
- 5 personalised action plan. The plan should support self-management of asthma, and
- 6 ensure that the person is receiving the best possible treatment for their current level
- 7 of illness. It focuses on the pharmacological management of chronic asthma, in
- 8 particular the treatment pathway for people with uncontrolled asthma. It also covers
- 9 adherence to treatment, risk stratification and self-management.
- 10 The guideline does not cover severe, difficult-to-control asthma or the management
- 11 of acute asthma attacks.
- 12 In 2018, new evidence was identified by the NICE surveillance team on increasing
- 13 the dose of inhaled corticosteroids within a self-management programme in children
- 14 and young people with asthma. Topic experts, including those who helped to
- 15 develop the 2017 guideline, agreed that the new evidence could have an impact on
- 16 the recommendations. This evidence has been reviewed and the recommendations
- 17 in this area updated.

## 18 **Finding more information and resources**

To find out what NICE has said on topics related to this guideline, see our web pageon <u>asthma</u>.

## 21 Update information

- 22 We have reviewed the evidence on increasing the dose of inhaled corticosteroids
- 23 within a self-management programme in children and young people with asthma.
- 24 Recommendations are marked **[2020]** if the evidence has been reviewed.

## 25 **Recommendations that have been deleted or changed**

- 26 We propose to delete a recommendation from the **[2017]** guideline. <u>Table 1</u> sets out
- 27 this recommendation and includes details of replacement recommendations. If there

- 1 is no replacement recommendation, an explanation for the proposed deletion is
- 2 given.
- 3 In recommendations shaded in grey and ending **[2017]**, we have not reviewed the
- 4 evidence. In some cases minor changes have been made for example, to update
- 5 links, or bring the language and style up to date without changing the intent of the
- 6 recommendation.
- 7 See also the previous NICE guideline and supporting documents.

#### 8 Table 1 Recommendations that have been deleted

Recommendation in [2017] guideline	Comment
<ul> <li>Within a self-management programme, consider an increased dose of ICS for 7 days for children and young people (aged 5 to 16) who are using an ICS in a single inhaler, when asthma control deteriorates. Clearly outline in the person's asthma action plan how and when to do this, and what to do if symptoms do not improve. When increasing ICS treatment: <ul> <li>consider quadrupling the regular ICS dose</li> <li>do not exceed the maximum licensed daily dose. (1.10.4)</li> </ul> </li> </ul>	Replaced by: For children and young people aged 5 to 16 with a diagnosis of asthma, include advice in their self-management plan on contacting a healthcare professional for a review, if their asthma control deteriorates (see also section 1.13 on monitoring asthma control). Encourage consistent ICS use to prevent deterioration and explain that there is no evidence of clinical benefit from increased doses of ICS. For people who have not maintained consistent ICS use, restarting ICS and taking it regularly may help them to regain control of their asthma. [2020] (1.10.3)

#### 9

10 © NICE 2019. All rights reserved. Subject to <u>Notice of rights</u>.

11 ISBN: